First Tracks Biotherapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to Guggenheim's 3rd Annual Healthcare Innovation Conference. My name is Yatin Suneja. It is my pleasure to welcome our next presenting company, First Tracks. From the company, we have the CEO, Dan Faga. Dan, why don't you maybe make some opening comments, give us some highlights. I mean, it's been a very, very productive year for you this year. Just orient our investors on not only the key molecule that you have, which is the CD122, but talk a little bit about the pipeline, and then I'll go into the Q&A.
All right. Good morning, everyone, or good afternoon, wherever we are. It's exciting. It's year one for First Tracks. We came in with a running start off our spin from Anaptys, and I agree with you. I think we've, sitting here a day in November, and off of our recent celiac data for our CD122 antagonist that we announced last month, we couldn't have had a better result. I think that we have a potential best-in-class program. The data exceeded ours and I think others' expectations with what we delivered in celiac, showing both a profound benefit on histology and symptoms in terms of preventing celiac worsening. We have a very ambitious plan in store for this program that we've outlined that's ongoing today and what we've previewed for 2027.
A year from now, we will be in four indications being developed in at least two therapeutic areas for this drug. We'll be moving to late-stage trials for celiac disease and hopefully have released equally positive data in EoE. That's just for the lead. Right out of the gate, we had three clinical-stage assets that we started the company with, including rosnilimab, a PD-1 depleter, and ANB101, which is a BDCA2 targeting agent, say, depleter of plasmacytoid dendritic cells. So three development stage programs. We still have our research engine in the company, and we are well-funded with over $350 million of cash sitting here today. So ambitious plans and a lot going on in the business.
Very good. Thank you for that. Let's start with the CD122 molecule first, just specifically on the molecule. To us, it looks differentiated. You have a different modality that you are offering, formulation that you're offering, and maybe the potency. Can you just talk about just purely how the asset looks when you do experiment on the preclinical data?
Sure. It is an antagonist of CD122, which presents in a receptor complex, either dimeric or trimeric receptor complex, on various types of immune cells. That is important because it offers a multimodal, almost multi-targeting agent. We often refer back to blocking IL-15 signaling. There are other IL-15 only targeting cytokine antagonists that exist that we are compared to, but we also importantly block IL-2 signaling. This is relevant in the diseases that I have already mentioned, but in celiac specifically, IL-2 is a cytokine that is released from CD4 cells when the byproduct of gluten is presented by APCs. CD4s get activated and release IL-2 immediately upon, within an hour of gluten exposure. So there is just really important proof of principle why the dual signal blocking just in that disease alone provides a lot of value. You are asking about preclinical data.
We have shown, I think, difference in potency from both the IL-15s as well as other CD122 programs on a reduction on the various cytokines, as well as CD4 T cells and CD8 T cells in various preclinical in vitro assays. I think also, again, head-to-head in different animal models as it relates to celiac disease or EoE. So I think we have shown the potency differentiation of a high affinity blocking both different cytokine signaling and then different immunology pathways, both Th1 and CD8. So I think there is a breadth of data that we have demonstrated. I think importantly, at least for today, we are subcutaneously administered, and that gives us administration advantage out of the gate in the ongoing trials relative to competition. I think then finally, and we will talk more about this, I think our clinical data, at least from what we are aware of today, looks differentiated.
All continues to add up.
Yeah And build on prior data sets that have been produced.
Yeah. Then maybe one more on high level. What is the development strategy? When I look at how you are disclosing the indication, you have been very careful in going after areas where I think the biology is a little bit more de-risked or less risk there. For example, like vitiligo, you only move forward after we have seen data in the space. As the aperture sort of widen for this mechanism, how much risk are you willing to take? How should we think about indication expansion? It is not that you have not have enough, you have enough, but just talk about the strategy.
Well, I think we have been balanced and thoughtful on how we have done this. If you go back one year, when we were moving into patient-driven studies, we announced we were in celiac disease. We waited a couple months, then we announced we were moving to EoE.
Yeah. Now, there was some proof of concept in a five-patient study of an IL-15 antagonist, not a CD122, where they showed EOS reduction and a symptomatic benefit in those five patients in an EoE trial.
We did come out and say we are going to run a broader 50-patient EoE study in February of this year, so that is ongoing. But the reason I bring that up is that is not fully de-risked in the same way I think we had more robust proof of concept in celiac disease.
Yeah. EoE has had plenty of challenges in development before with drugs that were being developed that in the end were not fully encompassing and driving towards tampering down inflammation.
They were great at targeting EOS directly.
Right? I am bringing you back there is that I think there is meaningful risk in where we are going, but we are following the biology and our own preclinical data. We generate animal model data that showed we were flooring not just EOS in this Aspergillus model, in both the lung and the esophagus, but we were also flooring ILC2s, which are one of the immune cells that are driving that disease, which we have seen being reduced with Dupixent in that disease. I think, EoE, we are the only player right now between the IL-15s and CD122s that are in a clinical trial. We took a leading role in EoE.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
